



Terrence Norchi, MD
Chief Executive Officer, President

Richard Davis
Chief Financial Officer

OTCQB: ARTH

Cautionary Statement Regarding Forward-Looking Statements




This presentation includes forward-looking statements. We make forward-looking statements, as defined by the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, and in some cases, you can identify these statements by forward-looking words such as “if,” “shall,” “may,” “might,” “will likely result,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “goal,” “objective,” “predict,” “potential” or “continue,” or the negative of these terms and other comparable terminology. These include statements regarding: our ability to leverage our technology platform in the development of our lead and potential pipeline product candidates; our ability to design and conduct development activities and studies and clinical trials for our lead and potential pipeline product candidates; the potential timing and results of any such clinical trials we may conduct; our ability to obtain regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes in order to market any planned products; our ability to achieve financial projections; and our ability to achieve milestones. The forward-looking statements in this presentation are based on management’s current expectations, estimates, forecasts and projections about the Company and its business, all of which could prove to be wrong. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for our current and future fiscal years could differ materially from the Company’s current expectations. Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, the following risks: we have estimated that we will have sufficient cash to operate our business for the near future, and we may not be able to obtain sufficient financing and/or establish necessary relationships with third parties to continue to pursue our business plan; the stockholder dilution that may result from future capital raising efforts and the exercise or conversion, as applicable of Arch’s outstanding options and warrants; anti-dilution protection afforded investors in prior financing transactions that may restrict or prohibit Arch’s ability to raise capital on terms favorable to the Company and its current stockholders; any development activities or clinical trials we may conduct may not produce favorable results; regulatory agencies may require that we undertake additional or more costly studies or clinical trials than we presently anticipate; we may never gain regulatory approval for any of our product candidates; we may not be able to protect our intellectual property rights; the intellectual property of others and any asserted claims of infringement; general business and economic conditions may limit our ability to obtain necessary capital; the consequences of competitive factors in the industry in which we operate may restrict the success of any product candidate we are able to commercialize, and we may not be able to attract or retain key personnel. More detailed information about us and the risk factors that may affect the realization of any forward-looking statements is set forth in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed on December 11, 2020 and subsequent filings with the SEC. Such documents may be read free of charge on the SEC’s internet site at <http://www.sec.gov>. You are cautioned not to place undue reliance on any forward-looking statements we make in this presentation given these risks and uncertainties, and all such statements are qualified in their entirety by this cautionary statement. All forward-looking statements speak only as of the date hereof, and we undertake no obligation to revise or update any forward-looking statement to reflect events or circumstances after the date hereof, except as otherwise required by law.

Who we are

Transforming advanced interventional wound care



- Inspired to solve problems
 - Improving patient health and quality of life
 - Enabling surgeons to do more with less
- Team attributes
 - Leadership
 - Clinical acumen
 - R&D track record
 - Commercial experience
 - Deep bench
- Extensive IP portfolio
 - License to MIT-developed technology
 - Arch-developed technology
 - Self-assembling nanofiber networks that control movement of fluids & enable healing
- In transition to commercialization
 - Providing a valuable solution
 - Seeking appropriate return



What we do


Addressing external and internal surgical/wound needs



Dermal Sciences: Products with Marketing Authorization

US: Under the supervision of a health care professional, **AC5 Advanced Wound System** is indicated for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds.

EU: **AC5 Topical Hemostat** is intended for use locally as a dressing and to control mild to moderate bleeding, each during the management of injured skin and the micro-environment of an acute surgical wound.



Biosurgery: Products in Development

AC5-G: hemostatic lift agent Endoscopic Mucosal Resection (EMR) & Submucosal Dissection (ESD)

AC5-V: hemostatic agent for vascular reconstruction procedures

¹ Anti-inflammatory effect of a self-assembling peptide (AC5®) in the lipopolysaccharide induced inflammation model of eye injury. Ellis-Behnke et al, MHSRS poster presentation 08/18

² Effects of a self-assembling peptide on second degree burn progression and healing in a porcine model. Davis et al, abstract accepted for Poster Presentation, SAWC Spring 2020

³ Effects of a self-assembling peptide on full-thickness wound healing in a porcine model. Gil et al, abstract accepted for Poster Presentation, SAWC Spring 2020

AC5 and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

What makes us distinctive

AC5 technology platform, mechanism, performance


AC5 Advanced Wound System



Self-Assembly



Electron Micrograph of Assembled Network



Designed to self-assemble in diverse situations to provide greater utility to clinicians and enable better outcomes for patients.

- Composed of naturally occurring proteogenic amino acids; biocompatible and biodegradable
- Forms physical barrier responsible for hemostatic and sealant properties
- Architecture resembles collagen I; provides ECM-like scaffold
- Enables cell migration/proliferation and repair of damaged tissue
- Entanglement with ECM components may provide additional mechanical strength at AC5®-wound interface
- Nanofibril non-covalent interactions allow for dynamic reassembly, or self-repairing

Achievements

2020 – significant year for clinical and preclinical results



25-year-old chronic refractory burn



Enabling aggressive surgical debridement and healing in a 10-year-old decubitus ulcer




Healing of a Complex Surgical Wound



➤ Also

- Refractory diabetic foot ulcers
- Refractory scleroderma with Raynaud phenomenon



University at Buffalo
The State University of New York

AdventHealth
Celebration

ARCH
THERAPEUTICS

Novel Self-assembling Agent, AC5-G™, for Use in Submucosal Lifting in Endoscopic Resection and Management of Gastrointestinal Bleeding

Eleanor C. Fung, MD¹
Jay Redan, MD²
Chirag Shah, PhD³
Terrence Norchi, MD³

¹University at Buffalo, Buffalo, NY
²Advent Health Celebration and University of Central Florida, Orlando, FL
³Arch Therapeutics Inc., Framingham, MA

Why now

Transition to commercial stage – US now and EU next



- Commercializing Dermal Sciences – larger market opportunity
 - US advanced wound dressing market in US ~\$2B
 - Competing products ~\$1,000 - 3,000 (and up)
 - Potentially limb & life saving
 - Pandemic lessons - chronic wounds are emergencies often overlooked
 - Selling a “system” - potential benefits during life of wound
 - Outcomes
 - Use in lower acuity settings
 - Elimination of costly products/procedures
 - Robust commercialization plan
 - Premium price commensurate with value proposition
 - Expanding team
 - Arch resources
 - Key Opinion Leaders to validate value proposition / generate data
 - Contract sales rep / administrative distribution partner alignment
 - Potential strategic alliance for targeted MD call points
 - VA/DOD hospital initial focus
- Advancing Biosurgery



Contact Information

235 Walnut Street, Suite 6
Framingham, MA 01702 USA

Investor Relations

Tel: 1.855.340.ARTH (2784)
investors@archtherapeutics.com